Agios Pharmaceuticals Inc. (NASDAQ:AGIO)’s share price dropped 4.1% during trading on Tuesday . The stock traded as low as $39.50 and last traded at $39.98, with a volume of 204,333 shares changing hands. The stock had previously closed at $41.71.

AGIO has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Wednesday, April 20th. SunTrust Banks Inc. initiated coverage on shares of Agios Pharmaceuticals in a report on Tuesday, March 29th. They issued a “buy” rating and a $57.00 target price on the stock. JPMorgan Chase & Co. raised shares of Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $50.00 to $62.00 in a report on Monday, June 13th. Credit Suisse Group AG reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Monday, April 25th. Finally, Vetr downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $68.42 price target on the stock. in a research note on Tuesday, June 7th. Six research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $69.67.

The firm’s market cap is $1.67 billion. The company has a 50 day moving average of $47.72 and a 200-day moving average of $45.77.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.18. The company earned $31.30 million during the quarter, compared to the consensus estimate of $20.94 million. During the same quarter last year, the company posted ($0.13) earnings per share. The firm’s revenue for the quarter was down 8.5% on a year-over-year basis. Analysts predict that Agios Pharmaceuticals Inc. will post ($3.46) earnings per share for the current year.

In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 627 shares of the stock in a transaction on Monday, April 25th. The stock was sold at an average price of $55.00, for a total value of $34,485.00. Following the completion of the transaction, the director now owns 128,429 shares in the company, valued at $7,063,595. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Scott Biller sold 27,500 shares of the stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $65.00, for a total value of $1,787,500.00. Following the completion of the transaction, the insider now owns 81,376 shares of the company’s stock, valued at approximately $5,289,440. The disclosure for this sale can be found here.

Several institutional investors recently modified their holdings of the stock. State Board of Administration of Florida Retirement System increased its position in shares of Agios Pharmaceuticals by 7.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,672 shares of the biopharmaceutical company’s stock valued at $1,472,000 after buying an additional 1,624 shares during the last quarter. Rhumbline Advisers increased its position in shares of Agios Pharmaceuticals by 2.5% in the fourth quarter. Rhumbline Advisers now owns 24,947 shares of the biopharmaceutical company’s stock valued at $1,620,000 after buying an additional 605 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Agios Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 31,258 shares of the biopharmaceutical company’s stock valued at $2,029,000 after buying an additional 1,740 shares during the last quarter. Columbia Wanger Asset Management LLC increased its position in shares of Agios Pharmaceuticals by 11.4% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 436,994 shares of the biopharmaceutical company’s stock valued at $28,370,000 after buying an additional 44,861 shares during the last quarter. Finally, GAM Holding AG increased its position in shares of Agios Pharmaceuticals by 210.9% in the fourth quarter. GAM Holding AG now owns 45,700 shares of the biopharmaceutical company’s stock valued at $2,967,000 after buying an additional 31,000 shares during the last quarter.

Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.